Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.

NCT07371325 is registered in ClinicalTrials.gov with Manuel Jesús Cuesta Zurita as lead sponsor.

NCT NCT07371325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.
Lead sponsor
Manuel Jesús Cuesta Zurita
Phase
Not applicable
Overall status
Completed
Start date
September 8, 2024
Completion date
January 23, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic abnormalities, postbiotic supplement, schizophrenia 1 (disorder)